Patents by Inventor Joerg Schlehofer

Joerg Schlehofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of parvovirus for eliminating cancer stem cells (CSCs)
    Patent number: 10525091
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 7, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
    Publication number: 20170266244
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 21, 2017
    Applicants: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Use of parvovirus for eliminating cancer stem cells (CSCs)
    Patent number: 9700588
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: July 11, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Method for Cancer Therapy Based on Co-Administration of a Parvovirus and a Cytokine
    Publication number: 20160367609
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-?, and the use of said composition for treatment of cancer, e.g., a brain tumor.
    Type: Application
    Filed: August 5, 2016
    Publication date: December 22, 2016
    Inventors: Irina KIPRIJANOVA, Manuel FISCHER, Jean ROMMELAERE, Joerg SCHLEHOFER, Karsten GELETNEKY
  • Method for brain cancer therapy by co-administration of a parvovirus and interferon-gamma
    Patent number: 9446099
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-?, and the use of said composition for treatment of cancer, e.g., a brain tumor.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: September 20, 2016
    Assignees: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Irina Kiprijanova, Manuel Fischer, Jean Rommelaere, Joerg Schlehofer, Karsten Geletneky
  • USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
    Publication number: 20130209413
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Application
    Filed: June 29, 2011
    Publication date: August 15, 2013
    Applicants: Ruprecht-Karls-Universitat Heidelberg, Deutsches Krebsforschungszentrum
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Parvovirus cancer therapy and combination with chemotherapy
    Patent number: 8414883
    Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 9, 2013
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Jean Rommelaere, Zahari Raykov, Joerg Schlehofer, Irina Kiprijanova, Tanja Heimberger, Assia Angelova, Karsten Geletneky, Marc Aprahamian
  • Method for Cancer Therapy Based on a Co-Administration of a Parvovirus and a Cytokine
    Publication number: 20120213734
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-?, and the use of said composition for treatment of cancer, e.g., a brain tumor.
    Type: Application
    Filed: May 19, 2010
    Publication date: August 23, 2012
    Applicants: Ruprecht-Karls-Universitaet Heidleberg, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
    Inventors: Irina Kiprijanova, Manual Fischer, Jean Rommelaere, Joerg Schlehofer, Karsten Geletneky
  • Parvovirus Cancer Therapy and Combination with Chemotherapy
    Publication number: 20110020287
    Abstract: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
    Type: Application
    Filed: December 23, 2008
    Publication date: January 27, 2011
    Inventors: Jean Rommelaere, Zahari Raykov, Joerg Schlehofer, Irina Kiprijanova, Tanja Heimberger, Assia Angelova, Karsten Geletneky, Marc Aprahamiam
  • Adeno-associated virus-its diagnostic use with early abortion
    Patent number: 6927281
    Abstract: The present invention relates to a method of detecting a causative agent of the so-called spontaneous early abortion by investigating patients' samples for the presence of adeno-associated virias DNA (AAV DNA), or AAV antigen or antibodies, preferably of the IgM type, directed to AAV. Furthermore, the present invention relates to antibodies suitable for said method.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: August 9, 2005
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Andrea Kern, Jürgen Kleinschmidt, Karsten Geletneky, Michéle Rabreau, Jörg Schlehofer, Edda Tobiasch
  • Use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy- induced resistance in cancer patients
    Patent number: 6743423
    Abstract: The invention relates to the use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy-induced resistance in patients who suffer from a cancer which is to be treated by radiotherapy or chemotherapy.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: June 1, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Mangus Von Knebel-Doeberitz, Petra Klein-Bauernschmitt, Harald Zur Hausen, Jörg Schlehofer